Risedronate Sodium Tablet, Film Coated
Product Images NDC 65862-870

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 65862-870). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Risedronate Fig1)

This is a figure showing the cumulative incidence of osteoporosis-related fractures over three years in patients treated with either a placebo, Risedronate Sodium 5 mg, or a combination of VERT MN and VERT NA. The percentage of patients who experienced fractures in specific areas (hip, leg, wrist, humerus, pelvis, and clavicle) is also shown.*

FDA Label Image

Figure 2 (Risedronate Fig2)

This is a description of a figure showing the change in bone mineral density (BMD) from baseline to a 2-year prevention study. The graph displays BMD data for different treatment groups, including placebo and treatment with risedronate sodium 5mg. The BMD change is expressed as the mean percentage change with the standard error (SE) represented in parentheses. The study evaluated BMD changes in the lumbar spine, femoral neck, and femoral trochanter.*

FDA Label Image

Fig3 (Risedronate Fig3)

This is a figure showing the Change in Bone Mineral Density (BMD) from Baseline in patients who recently started Glucocorticoid Therapy. The graph compares the mean percentage change in BMD for patients taking Placebo and Risedronate Sodium 5mg. The BMD change is measured for Lumbar Spine, Femoral Neck, and Trochanter. No additional information is available from the given text.*

FDA Label Image

Fig4 (Risedronate Fig4)

The text provides a graphical representation of the mean percentage change in bone mineral density (BMD) along with the standard error (SE) for patients on long-term glucocorticoid therapy. The graph displays the BMD changes from baseline for two groups of patients, one treated with placebo, and the other treated with risedronate sodium 5 mg. The BMD changes are compared for three different bone sites, including the lumbar spine, femoral neck, and femoral trochanter. Useful information is not available without the graph.*

FDA Label Image

Fig5 (Risedronate Fig5)

The text describes the incidence of vertebral fractures in patients either initiating or continuing glucocorticoid therapy. The incidence is represented in a graph where the placebo group had a 24% incidence rate, the Risedronate Sodium 5mg group had an 18% incidence rate, and the combined patient group had rates ranging from 6% to 12%. The sample sizes of each group are also provided.*

FDA Label Image

Figure 6 (Risedronate Fig6)

This is a graph showing the mean percent change from baseline in serum alkaline phosphatase excess by visit for two medications: DIDRONEL 400 mg and Risedronate Sodium 30 mg. The x-axis shows visit days and the y-axis shows the percent change from baseline. The graph shows change over a period of 600 days with treatment, follow-up, and extended follow-up.*

FDA Label Image

Package Label-principal Display Panel (150 mg Blister Card (1 Unit-of-use))

This is a medication package for Risedronate Sodium tablets. Each tablet contains 150mg of Risedronate Sodium. Adult dosage should be determined by a healthcare professional. The package is child-resistant and should be stored at 20-25°C (68-77°F). The instructions for opening the package are provided. The product is manufactured in India and distributed by Aurobindo Pharma USA, Inc. The package contains one-month supply of tablets and should be refilled monthly. This medication requires a prescription.*

FDA Label Image

Package Label-principal Display Panel (150 mg Blister Carton (1 Unit-of-use))

This is a medication guide for Risedronate Sodium Tablet USP, which is taken once a month. The tablet should be swallowed on the same day each month with plain water, before eating or drinking anything, and patients should avoid lying down, eating, drinking or taking other medications for at least 30 minutes. The dose should be taken as prescribed by a healthcare provider. Full patient information is available in the enclosed Medication Guide.*

FDA Label Image

Chemical Structure (Risedronate Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.